Profile data is unavailable for this security.
About the company
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
- Revenue in USD (TTM)0.00
- Net income in USD-117.30m
- Incorporated2023
- Employees45.00
- LocationenGene Holdings Inc4868 Rue Levy, Suite 220SAINT-LAURENT H4R 2P1CanadaCAN
- Phone+1 (514) 332-4888
- Websitehttps://engene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design Therapeutics Inc | 0.00 | -67.45m | 573.63m | 55.00 | -- | 2.87 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| ProKidney Corp | 744.00k | -71.03m | 595.65m | 204.00 | -- | -- | -- | 800.61 | -0.5443 | -0.5443 | 0.0057 | -3.41 | 0.0018 | -- | 0.2347 | 3,647.06 | -38.54 | -- | -- | -- | -- | -- | -21,403.63 | -- | -- | -- | 0.0003 | -- | -- | -- | -72.51 | -- | -- | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 595.69m | 214.00 | -- | 3.68 | -- | 99.66 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 599.66m | 409.00 | -- | -- | -- | 21.87 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 611.31m | 15.00 | -- | 9.84 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 655.11m | 45.00 | -- | 3.03 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
| Replimune Group Inc | 0.00 | -314.85m | 658.10m | 479.00 | -- | 3.01 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| LB Pharmaceuticals Inc | 0.00 | -18.80m | 667.66m | 16.00 | -- | 1.90 | -- | -- | -0.82 | -0.82 | 0.00 | 12.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -905.61 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 684.69m | 111.00 | -- | 1.52 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 693.93m | 5.00 | -- | 136.38 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 701.26m | 45.00 | -- | 2.90 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Annexon Inc | 0.00 | -208.88m | 706.83m | 99.00 | -- | 3.49 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 723.12m | 192.00 | -- | 2.98 | -- | 6.95 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 728.94m | 574.00 | 124.24 | 7.15 | 51.69 | 6.80 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Personalis Inc | 69.10m | -73.88m | 729.08m | 229.00 | -- | 4.25 | -- | 10.55 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
Data as of Feb 13 2026. Currency figures normalised to enGene Holdings Inc's reporting currency: US Dollar USD
37.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 11 Nov 2025 | 5.87m | 8.76% |
| Kynam Capital Management LPas of 30 Sep 2025 | 4.99m | 7.46% |
| Deep Track Capital LPas of 31 Dec 2025 | 4.38m | 6.54% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 2.32m | 3.47% |
| Braidwell LPas of 30 Sep 2025 | 2.27m | 3.38% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.39m | 2.07% |
| Point72 Asset Management LPas of 30 Sep 2025 | 1.21m | 1.80% |
| Adage Capital Management LPas of 30 Sep 2025 | 1.00m | 1.49% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 950.00k | 1.42% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 699.09k | 1.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
